Funding for this research was provided by:
Seventh Framework Programme (No.115010)
Received: 25 November 2020
Accepted: 14 December 2020
First Online: 7 January 2021
Change Date: 8 February 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/S12931-021-01642-X
Ethics approval and consent to participate
: All participants gave signed informed consent to participate in the study, which was approved by the local Ethics Committees.
: Dr Djukanovic reports receiving fees for lectures at symposia organised by Novartis, AstraZeneca and TEVA, consultation for TEVA and Novartis as member of advisory boards, and participation in a scientific discussion about asthma organised by GlaxoSmithKline. He is a co-founder and current consultant, and has shares in Synairgen, a University of Southampton spin out company. Dr. Sterk has nothing to disclose. Dr. Sterk reports grants from public–private funding by the Innovative Medicines Initiative (IMI) covered by the European Union (EU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), during the conduct of the study. Dr Chung has received honoraria for participating in Advisory Board meetings of GSK, AZ, Roche, Novartis, Merck, BI, TEVA and Shionogi regarding treatments for asthma, chronic obstructive pulmonary disease and chronic cough and has also been renumerated for speaking engagements. Dr. Dahlén reports personal fees from AZ, Cayman Chemical, GSK, Novartis, Sanofi, Regeneron, TEVA, outside the submitted work. Mr Versi, Dr Kermani, Dr Song, Mr Badi, Dr Guo, Dr Sun, Dr Bhavsar, Dr Howarth and Dr Adcock have nothing to disclose.